Gemini Therapeutics, Inc. (GMTX) Stock Moves 2.68%: What You Should Know
Gemini Therapeutics, Inc. (GMTX) stock is up 2.68% in the last day. For details on what happened in the market, see our analysis.
07:00, 27 June 2022Trade Gemini Therapeutics, Inc. - GMTX CFD
Gemini Therapeutics, Inc. live chart
Still looking for a broker you can trust?
Capital.com Group 400,000+
Traders
90,000+
Active clients monthly
$65,000,000+
Monthly investing volume
$29,000,000+
Try now Withdrawn each month
- Summary
- Historical Data
Trading Conditions
- Long position overnight fee
- -0.0225%
- Short position overnight fee
- -0.0219%
- Overnight fee time
- 21:00 (UTC)
- Min traded quantity
- 1
- Currency
- USD
- Margin
- 20%
- Stock exchange
- United States of America
- Commission on trade
- 0%
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jun 24, 2022 | 1.55 | 0.06 | 4.03% | 1.49 | 1.78 | 1.45 |
| Jun 23, 2022 | 1.51 | 0.08 | 5.59% | 1.43 | 1.51 | 1.43 |
| Jun 22, 2022 | 1.47 | 0.11 | 8.09% | 1.36 | 1.47 | 1.35 |
| Jun 21, 2022 | 1.40 | -0.04 | -2.78% | 1.44 | 1.44 | 1.34 |
| Jun 17, 2022 | 1.34 | 0.04 | 3.08% | 1.30 | 1.40 | 1.30 |
| Jun 16, 2022 | 1.39 | 0.03 | 2.21% | 1.36 | 1.40 | 1.29 |
| Jun 15, 2022 | 1.41 | 0.05 | 3.68% | 1.36 | 1.43 | 1.36 |
| Jun 14, 2022 | 1.42 | 0.06 | 4.41% | 1.36 | 1.46 | 1.34 |
| Jun 13, 2022 | 1.48 | 0.07 | 4.96% | 1.41 | 1.53 | 1.34 |
| Jun 10, 2022 | 1.43 | 0.05 | 3.62% | 1.38 | 1.48 | 1.36 |
| Jun 9, 2022 | 1.46 | 0.10 | 7.35% | 1.36 | 1.56 | 1.25 |
| Jun 8, 2022 | 1.43 | 0.02 | 1.42% | 1.41 | 1.45 | 1.36 |
| Jun 7, 2022 | 1.50 | 0.23 | 18.11% | 1.27 | 1.56 | 1.27 |
| Jun 6, 2022 | 1.32 | 0.05 | 3.94% | 1.27 | 1.34 | 1.24 |
| Jun 3, 2022 | 1.25 | 0.10 | 8.70% | 1.15 | 1.28 | 1.15 |
| Jun 2, 2022 | 1.17 | -0.06 | -4.88% | 1.23 | 1.27 | 1.17 |
| Jun 1, 2022 | 1.23 | 0.01 | 0.82% | 1.22 | 1.29 | 1.20 |
| May 31, 2022 | 1.23 | 0.03 | 2.50% | 1.20 | 1.24 | 1.18 |
| May 27, 2022 | 1.21 | 0.00 | 0.00% | 1.21 | 1.22 | 1.18 |
| May 26, 2022 | 1.15 | -0.05 | -4.17% | 1.20 | 1.25 | 1.15 |
Content 2
Content 2
Key Stats
| Prev. Close* | 1.55 |
| Open* | 1.53 |
| Day's Range* | 1.52 - 1.52 |
| 1-Year Change* | 0.66% |
| Volume | N/A |
| Average Vol. (3m) | 5.89554 |
| 52 wk Range | N/A |
| Market Cap | 55.3064 |
| P/E Ratio | N/A |
| Shares Outstanding | 43.23M |
| Revenue | N/A |
| EPS | -1.57797 |
| Dividend (Yield %) | N/A |
| Beta | N/A |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
Gemini Therapeutics, Inc. Company profile
About Gemini Therapeutics Inc
Gemini Therapeutics, Inc., formerly FS Development Corp., is a clinical-stage precision medicine company. The Company is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The Company's lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH to construct that express GEM103 continuously at a therapeutic level. Its pipeline is designed to develop treatments for genetically subpopulations of patients suffering from dry AMD and linked diseases. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Gemini Therapeutics Inc revenues was not reported. Net loss increased from $812K to $71.9M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.05 to -$1.78.
| Industry: | Biotechnology & Medical Research (NEC) |
300 One Kendall Square, 3Rd Floor
Suite 4500
CAMBRIDGE
MASSACHUSETTS 02139
US
News
M&A to be a norm for DAOs says Chainalysis
DAOs such as Uniswap, Maker and AAVE could benefit from integrating
12:00, 27 June 2022
Overvalued assets could magnify global economic slowdown, BIS warns
‘Central banks must act quickly to keep inflation under control’
11:31, 27 June 2022
Thyssenkrupp stock down 39%: Can steelmakers stand the heat?
Global steelmakers face massive write-down risk – which stocks are exposed to the heat?
11:23, 27 June 2022
Precious metals boosted by G7 countries considering ban on Russian gold
Precious metals gold, silver, platinum and palladium were all up on Monday morning, starting the week on a high note
10:00, 27 June 2022
FOCUS- ‘Off the charts’ chemical shortages hit U.S. farms
Shortages have disrupted U.S. growers' production strategies and raised their costs
09:59, 27 June 2022People Also Watch
Gold Spot
1,825.46 Price
| Long position overnight fee | -0.0102% |
| Short position overnight fee | -0.0092% |
| Overnight fee time | 21:00 (UTC) |
| Spread | 0.18 |
Trade now
Still looking for a broker you can trust?
Join the 400.000+ traders worldwide that chose to trade with Capital.com
